Differential expression of Protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples

International Journal of Cancer

Volumn 113, Issue 3, 2005, Pages 372-378

  Grisaru Granovsky, Sorina ^a,b   Salah, Zaidoun ^a   Maoz, Myriam ^a   Pruss, Diana ^a   Beller, Uziel ^b   Bar Shavit, Rachel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Carcinoma; Extracellular matrix; Human ovarian tissues; PAR; Proteases; Thrombin

Indexed keywords

CD51 ANTIGEN; FOCAL ADHESION KINASE; PROTEINASE ACTIVATED RECEPTOR 1;

ARTICLE; CANCER STAGING; CELL SURFACE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; EPITHELIUM; FEMALE; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; INTEGRINS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; OVARY; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; RECEPTOR, PAR-1; RECEPTORS, VITRONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 11144285417     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20607     Document Type: Article

References (43)

1. Vu T-K, Hung HDT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991;64:1057-68.
2. Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pages G, Pavirani A, Lecocq JP, Pouyssegur J. Van Obberghen-Schilling E. cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 1991;288:123-8.
3. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998;394:690-4.
4. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000;404:609-13.
5. Even-Ram SC, Grisaru-Granovsky S, Pruss D, Maoz M, Salah Z, Yong-Jun Y, Bar-Shavit R. The pattern of expression of protease-activated receptors (PAR) during early trophoblast development. J Pathol 2003;200:47-52.
6. Even-Ram S, Uziely B, Cohen P, Ginzburg, Y, Reich R, Vlodavsky I, Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4:909-14.
7. Martin CB, Mahon GM, Klinger MB, Kay RJ, Symons M, Der CJ, Whitehead IP. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways Oncogene 2001; 20:1953-63.
8. Kruk PA, Uitto VJ, Firth JD, Dedhar S, Auersperg N. Reciprocal interactions between human ovarian surface epithelium cells and adjacent extracellular matrix. Exp Cell Res 1994;215:97-108.
9. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994;73:1859-64.
10. Aoki Y, Kawada N, Tanaka K. Early form of ovarian cancer originating in inclusion cysts. A case report. J Reprod Med 2000;45:159-61.
11. Feeley KM, Wells M. 2001. Precursor lesions of ovarian epithelium malignancy. Histopathology 2001;38:87-95.
12. Roskelley CD, Bissell MJ. The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol 2002;12:97-104.
13. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
14. Groeger AM, Esposito V, De Luca A, Cassandro R, Tonini G, Ambrogi V, Baldi F, Goldfarb R, Mineo TC, Baldi A, Wolner E. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-XL in resected non small cell lung cancers. Histopathology 2004;44:54-63.
15. Cohen Even-Ram S, Maoz M, Pokroy E, Reich R, Katz B-Z, Gutwein P, Altevogt P, Bar-Shavit R. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the αvβ5 integrin. J Biol Chem 2001;276:10952-62.
16. Gershenson DM, Silva EG. Serous ovarian tumors of "low malignant potential" with peritoneal implants. Cancer 1990;65:578-85.
17. Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C. Serous "low malignant potential" tumors of the ovary with noninvasive peritoneal implants. Cancer 1998;83:2157-63.
18. Dauplat J, Nieberg RK, Hacker NF. Central nervous system metastases in epithelium ovarian carcinoma. Cancer 1987;60:2559-62.
19. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian "low malignant potential" tumors and stage I carcinomas. Hum Pathol 1995;26:387-92.
20. Skomedal H, Kristensen GB, Abeler VM, Borresen-Dale AL, Trope C, Holm R. p53 protein accumulation and gene mutation in relation to over-expression of MDM2 protein in ovarian "low malignant potential" tumors and stage I carcinomas. J Pathol 1997;181:158-65.
21. Tangir J, Loughridge NS, Berkowitz RS, Muto MG, Bell DA, Welch WR, Mok SC. Frequent microsatellite instability in epithelium "low malignant potential" ovarian tumors. Cancer Res 1996;56:2501-5.
22. King BL, Carcangiu ML, Carter D, Kiechle M, Pfisterer J, Pfleiderer A, Kacinski BM. Microsatellite instability in ovarian neoplasms. Br J Cancer 1995;72:376-82.
23. Cheng PC, Gosewehr JA, Kim TM, Velicescu M, Wan M, Zheng J, Felix JC, Cofer KF, Luo P, Biela BH, Godorov G, Dubeau L. 1996. Potential role of the inactivated X chromosome in ovarian epithelium tumor development. J Natl Cancer Inst 1996;88:510-8.
24. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih M. Mutations in BRAF and KRAS characterize the development of low grade ovarian serous carcinoma. J Nat Cancer Inst 2003;95: 484-5.
25. Russel SEH, McCluggage WG. A multistep model for ovarian tumorigenesis; the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004;203:617-9.
26. Watson RH, Neville PJ, Roy WJ Jr, Hitchcock A, Campbell IG. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis. Oncogene 1998;17:207-12.
27. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, Lu KH, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, et al. Outcome of reproductive age women with stage 1A or 1C invasive epithelium ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:1-7.
28. Illmensee K, Minz B. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci USA 1976;73:549-53.
29. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 2001;158:2031-41.
30. Roskelly CD, Bissell MJ. The dominance of the microenvironment in breast and ovarian cancer. Cancer Biol 2002;12:97-104.
31. Skubitz APN, Bast RC, Wayner EA, Letoureau PC, Wilke MS. Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 1996;148:1445-61.
32. Strobel T, Cannistra SA. β1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 1999;73:362-7.
33. Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin -1 acts as a natural mammary tumor promoter. Oncogene 2000;19:1102-13.
34. Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000;19:5606-13.
35. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2001;1540:1-21.
36. Judson PL, He X, Cance WG, Van Le L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 1999;86:1551-6.
37. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S, Xu L. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000;6:2417-23.
38. Hecker TP, Grammer JR, Gillespie GY, Stewart J Jr, Gladson CL. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res 2000;62:2699-707.
39. Hauck CR, Hsia DA, Puente XS, Cheresh DA, Schlaepfer DD. FRNK blocks v-Src-stimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J 2002;21:6289-302.
40. Ilic D, Kanazawa S, Furuta Y, Yamamoto T, Aizawa S. Impairment of mobility in endodermal cells by FAK deficiency. Exp Cell Res 1996;222:298-303.
41. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000;2:249-56.
42. Cary LA, Chang JF, Guan JL. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci 1996;109:1787-94.
43. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, Spencer KS, Cheresh DA, et al. Differential regulation of cell motility and invasion by FAK. J Cell Biol 2003;160:753-67.